The Diagnostics Pipeline: FDA Issues Groundbreaking Clearance for an RSV Vaccine
In early May, GSK’s Arexvy became the first RSV vaccine to be cleared by the FDA for use in the US in adults aged 60 and up.

Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article